Beam Therapeutics (BEAM)
Beam Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
27.5M
Short interest
settlement 2026-09-30
15.3
Days to cover
+2.7 days vs prior
49.3%
Short share of volume
2026-10-09
2,930
Fails to deliver
settlement 2026-09-04
Tue 3 Nov
Next earnings
estimated date
-$434K
Insider flow, 90 days
0 buys, 2 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in BEAM is 27,548,815 shares, up 1,746,148 shares over the last month. Over the last 48 readings it ranged from 9,237,141 shares (14 February 2025) to 28,309,079 shares (15 June 2026). The latest reading sits at the top of that range. At the reported average volume of 1.8M shares a day that is 15.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/beam" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 27,548,815 | +6.4% | 1,800,518 | 15.30 |
| 2026-09-15 | 25,884,796 | +0.3% | 2,056,785 | 12.59 |
| 2026-08-31 | 25,802,667 | +5.9% | 1,738,348 | 14.84 |
| 2026-08-14 | 24,374,054 | +3.7% | 1,515,880 | 16.08 |
| 2026-07-31 | 23,498,484 | +1.2% | 2,078,520 | 11.31 |
| 2026-07-15 | 23,215,449 | +1.5% | 2,599,432 | 8.93 |
| 2026-06-30 | 22,881,525 | -19.2% | 2,731,836 | 8.38 |
| 2026-06-15 | 28,309,079 | +31.9% | 1,991,103 | 14.22 |
| 2026-05-29 | 21,455,853 | -19.1% | 1,829,055 | 11.73 |
| 2026-05-15 | 26,515,763 | +26.6% | 2,109,796 | 12.57 |
| 2026-04-30 | 20,936,705 | -5.8% | 2,202,408 | 9.51 |
| 2026-04-15 | 22,221,090 | -4.9% | 2,010,871 | 11.05 |
| 2026-03-31 | 23,361,096 | +9.7% | 2,193,133 | 10.65 |
| 2026-03-13 | 21,302,875 | -2.7% | 2,007,990 | 10.61 |
| 2026-02-27 | 21,890,367 | +8.2% | 1,607,804 | 13.62 |
| 2026-02-13 | 20,227,236 | +4.2% | 1,499,701 | 13.49 |
| 2026-01-30 | 19,409,310 | -3.2% | 1,920,572 | 10.11 |
| 2026-01-15 | 20,044,367 | -1.2% | 2,343,656 | 8.55 |
| 2025-12-31 | 20,295,552 | +2.6% | 1,295,727 | 15.66 |
| 2025-12-15 | 19,788,474 | -5.5% | 1,808,901 | 10.94 |
| 2025-11-28 | 20,951,122 | +1.9% | 2,022,907 | 10.36 |
| 2025-11-14 | 20,550,660 | +3.7% | 2,374,359 | 8.66 |
| 2025-10-31 | 19,823,221 | -2.9% | 2,605,302 | 7.61 |
| 2025-10-15 | 20,424,008 | -4.5% | 2,429,501 | 8.41 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of BEAM volume is 49.3%, down 23.5 points over the last five sessions. Over the last 30 readings it ranged from 45.5% (1 September 2026) to 80.6% (18 September 2026). The latest reading is 17.5 points below the 30-session average of 66.8%, on 706K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 348K | 706K | 49.3% | 16 |
| 2026-10-08 | 413K | 587K | 70.4% | 0 |
| 2026-10-07 | 611K | 853K | 71.6% | 22 |
| 2026-10-06 | 788K | 1.1M | 72.8% | 145 |
| 2026-10-05 | 417K | 599K | 69.6% | 0 |
| 2026-10-02 | 424K | 582K | 72.8% | 4 |
| 2026-10-01 | 429K | 648K | 66.2% | 17,230 |
| 2026-09-30 | 397K | 561K | 70.7% | 1 |
| 2026-09-29 | 380K | 548K | 69.4% | 1,000 |
| 2026-09-28 | 297K | 503K | 59.0% | 1,001 |
| 2026-09-25 | 341K | 484K | 70.5% | 1,338 |
| 2026-09-24 | 685K | 969K | 70.7% | 404 |
| 2026-09-23 | 657K | 816K | 80.5% | 1,069 |
| 2026-09-22 | 585K | 808K | 72.4% | 585 |
| 2026-09-21 | 686K | 905K | 75.8% | 1,512 |
| 2026-09-18 | 595K | 739K | 80.6% | 0 |
| 2026-09-17 | 910K | 1.2M | 79.0% | 0 |
| 2026-09-16 | 566K | 746K | 75.9% | 0 |
| 2026-09-15 | 688K | 911K | 75.6% | 115 |
| 2026-09-14 | 394K | 571K | 69.0% | 3 |
| 2026-09-11 | 284K | 453K | 62.7% | 226 |
| 2026-09-10 | 478K | 790K | 60.6% | 35 |
| 2026-09-09 | 943K | 1.4M | 65.7% | 72,772 |
| 2026-09-08 | 1.9M | 2.9M | 64.8% | 93,671 |
| 2026-09-04 | 300K | 536K | 55.9% | 0 |
| 2026-09-03 | 311K | 544K | 57.2% | 100 |
| 2026-09-02 | 273K | 496K | 55.0% | 1,261 |
| 2026-09-01 | 186K | 409K | 45.5% | 724 |
| 2026-08-31 | 258K | 457K | 56.5% | 920 |
| 2026-08-28 | 313K | 533K | 58.7% | 9,725 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 4 September 2026, the fails-to-deliver balance in BEAM is 2,930 shares, up 495 shares over the last settlement date. Over the last 30 readings it ranged from 9 shares (13 August 2026) to 420,925 shares (15 May 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-04 | 2,930 | $29.46 | $86K |
| 2026-09-03 | 2,435 | $29.29 | $71K |
| 2026-08-19 | 3,846 | $26.57 | $102K |
| 2026-08-18 | 5,236 | $27.10 | $142K |
| 2026-08-17 | 9,538 | $26.75 | $255K |
| 2026-08-13 | 9 | $26.71 | $240 |
| 2026-08-05 | 49,765 | $28.35 | $1.4M |
| 2026-08-04 | 9,093 | $25.91 | $236K |
| 2026-07-31 | 6,414 | $26.49 | $170K |
| 2026-07-20 | 105 | $27.53 | $3K |
| 2026-07-10 | 100 | $35.82 | $4K |
| 2026-07-09 | 3,306 | $36.88 | $122K |
| 2026-07-02 | 443 | $33.48 | $15K |
| 2026-07-01 | 400 | $34.32 | $14K |
| 2026-06-30 | 3,043 | $34.95 | $106K |
| 2026-06-29 | 26,787 | $34.81 | $932K |
| 2026-06-22 | 500 | $34.14 | $17K |
| 2026-06-17 | 32 | $30.99 | $992 |
| 2026-06-11 | 24,640 | $29.49 | $727K |
| 2026-06-10 | 251 | $30.47 | $8K |
| 2026-06-08 | 33,539 | $29.40 | $986K |
| 2026-06-03 | 73,137 | $28.96 | $2.1M |
| 2026-06-01 | 133 | $32.93 | $4K |
| 2026-05-20 | 10,165 | $26.33 | $268K |
| 2026-05-15 | 420,925 | $29.53 | $12.4M |
| 2026-05-11 | 17 | $32.32 | $549 |
| 2026-05-08 | 21,010 | $31.47 | $661K |
| 2026-05-07 | 20 | $32.34 | $647 |
| 2026-04-30 | 28 | $29.38 | $823 |
| 2026-04-29 | 13,405 | $30.56 | $410K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at BEAM reported 2 open-market sells worth $434K in the last 90 days and no open-market buys. Latest filing: Cavanagh Bethany J (SVP, Finance and Treasurer) on 2026-10-01.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Cavanagh Bethany J | SVP, Finance and Treasurer | Sell | 187 | $24.41 | $5K | 51K |
| 2026-09-24 | Ciaramella Giuseppe | President | Gift | 123K | $0.00 | $0 | 131K |
| 2026-07-27 | Simon Amy | Chief Medical Officer | Sell | 17K | $25.74 | $429K | 86K |
| 2026-06-30 | Evans John M. | CEO | Sell | 2K | $34.84 | $66K | 1.0M |
| 2026-06-30 | Evans John M. | CEO | Sell | 23K | $34.26 | $791K | 1.0M |
| 2026-06-30 | Evans John M. | CEO | Option exercise | 25K | $1.03 | $26K | 1.1M |
| 2026-06-30 | Simon Amy | Chief Medical Officer | Sell | 373 | $34.73 | $13K | 102K |
| 2026-06-29 | Evans John M. | CEO | Sell | 12K | $35.91 | $416K | 1.0M |
| 2026-06-29 | Evans John M. | CEO | Sell | 13K | $35.13 | $472K | 1.1M |
| 2026-06-29 | Evans John M. | CEO | Option exercise | 6K | $1.03 | $7K | 1.1M |
| 2026-06-29 | Evans John M. | CEO | Option exercise | 19K | $0.67 | $13K | 1.1M |
| 2026-06-26 | FMR LLC | 10% owner, See Remark 1 | Sell | 251K | $35.26 | $8.9M | 855K |
| 2026-06-25 | FMR LLC | 10% owner, See Remark 1 | Sell | 33K | $35.12 | $1.2M | 1.1M |
| 2026-06-17 | Ciaramella Giuseppe | President | Option exercise | 29K | $1.03 | $30K | 254K |
| 2026-06-17 | Ciaramella Giuseppe | President | Option exercise | 7K | $0.67 | $4K | 225K |
| 2026-04-01 | Evans John M. | CEO | Sell | 30K | $24.58 | $739K | 1.0M |
| 2026-04-01 | Simon Amy | Chief Medical Officer | Sell | 7K | $24.58 | $165K | 103K |
| 2026-04-01 | Cavanagh Bethany J | SVP, Finance and Treasurer | Sell | 3K | $24.58 | $80K | 51K |
| 2026-04-01 | Bellon Christine | Chief Legal Officer | Sell | 6K | $24.58 | $146K | 110K |
| 2026-04-01 | Ciaramella Giuseppe | President | Sell | 12K | $24.58 | $290K | 218K |
| 2026-03-31 | Evans John M. | CEO | Grant | 90K | $0.00 | $0 | 1.1M |
| 2026-03-31 | Evans John M. | CEO | Sell | 25K | $22.76 | $569K | 987K |
| 2026-03-31 | Evans John M. | CEO | Option exercise | 25K | $0.67 | $17K | 1.0M |
| 2026-03-31 | Bellon Christine | Chief Legal Officer | Grant | 20K | $0.00 | $0 | 116K |
| 2026-03-31 | Cavanagh Bethany J | SVP, Finance and Treasurer | Grant | 20K | $0.00 | $0 | 55K |
| 2026-03-31 | Simon Amy | Chief Medical Officer | Grant | 32K | $0.00 | $0 | 109K |
| 2026-03-31 | Emany Sravan Kumar | Chief Financial Officer | Grant | 32K | $0.00 | $0 | 105K |
| 2026-03-31 | Ciaramella Giuseppe | President | Grant | 40K | $0.00 | $0 | 230K |
| 2026-03-30 | Evans John M. | CEO | Sell | 25K | $22.37 | $559K | 987K |
| 2026-03-30 | Evans John M. | CEO | Option exercise | 25K | $0.67 | $17K | 1.0M |
| 2026-02-24 | Ciaramella Giuseppe | President | Sell | 35K | $32.00 | $1.1M | 190K |
| 2026-02-24 | Ciaramella Giuseppe | President | Option exercise | 35K | $17.00 | $595K | 225K |
| 2026-01-30 | Evans John M. | CEO | Sell | 3K | $29.00 | $84K | 987K |
| 2026-01-30 | Evans John M. | CEO | Sell | 22K | $28.27 | $625K | 990K |
| 2026-01-30 | Evans John M. | CEO | Option exercise | 25K | $0.67 | $17K | 1.0M |
| 2026-01-29 | Evans John M. | CEO | Sell | 9K | $29.74 | $258K | 987K |
| 2026-01-29 | Evans John M. | CEO | Sell | 16K | $29.19 | $477K | 995K |
| 2026-01-29 | Evans John M. | CEO | Option exercise | 6K | $0.67 | $4K | 1.0M |
| 2026-01-29 | Evans John M. | CEO | Option exercise | 19K | $0.67 | $13K | 1.0M |
| 2026-01-22 | Cavanagh Bethany J | SVP, Finance and Treasurer | Sell | 6K | $35.00 | $217K | 35K |
| 2026-01-22 | Bellon Christine | Chief Legal Officer | Sell | 1K | $34.00 | $47K | 96K |
| 2026-01-20 | Cavanagh Bethany J | SVP, Finance and Treasurer | Sell | 3K | $30.12 | $91K | 41K |
| 2026-01-15 | Bellon Christine | Chief Legal Officer | Sell | 559 | $35.40 | $20K | 97K |
| 2026-01-15 | Bellon Christine | Chief Legal Officer | Sell | 16K | $34.72 | $554K | 98K |
| 2026-01-15 | Bellon Christine | Chief Legal Officer | Sell | 2K | $33.62 | $71K | 114K |
| 2025-12-31 | Emany Sravan Kumar | Chief Financial Officer | Sell | 6K | $27.10 | $171K | 74K |
| 2025-12-31 | Bellon Christine | Chief Legal Officer | Sell | 1K | $27.10 | $34K | 116K |
| 2025-12-31 | Simon Amy | Chief Medical Officer | Grant | 13K | $0.00 | $0 | 77K |
| 2025-10-27 | FMR LLC | 10% owner, See Remark 1 | Sell | 459 | $26.68 | $12K | 14 |
| 2025-10-06 | FMR LLC | 10% owner, See Remark 1 | Gift | 1.2M | $0.00 | $0 | 841K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON17 Form 144 notices on file for BEAM worth $13.4M at the prices reported; 1 in the last 90 days worth $429K. Latest: AMY SIMON filed on 2026-07-27 to sell 16,677 shares ($429K) from 2026-07-27.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-07-27 | AMY SIMONOfficer | 17K | $429K | 0.016% | 2026-07-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-30 | JOHN M EVANSOfficer, Director | 25K | $858K | 0.024% | 2026-06-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-29 | JOHN M EVANSOfficer, Director | 25K | $887K | 0.024% | 2026-06-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-14 | CAROLE HODirector | 88K | $2.7M | 0.086% | 2026-04-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-31 | JOHN M EVANSOfficer, Director | 25K | $569K | 0.025% | 2026-03-31 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-31 | CHRISTINE BELLONOfficer | 20K | $438K | 0.020% | 2026-04-02 | ETRADE FINANCIAL CORPORATION |
| 2026-03-31 | GIUSEPPE CIARAMELLAOfficer | 26K | $575K | 0.026% | 2026-04-02 | ETRADE FINANCIAL CORPORATION |
| 2026-03-31 | AMY SIMONOfficer | 20K | $438K | 0.020% | 2026-04-02 | ETRADE FINANCIAL CORPORATION |
| 2026-03-31 | JOHN M. EVANSOfficer, Director | 67K | $1.5M | 0.066% | 2026-04-02 | ETRADE FINANCIAL CORPORATION |
| 2026-03-30 | JOHN M EVANSOfficer, Director | 25K | $559K | 0.025% | 2026-03-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-24 | GIUSEPPE CIARAMELLAOfficer | 35K | $1.1M | 0.034% | 2026-02-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-30 | JOHN M EVANSOfficer, Director | 25K | $709K | 0.025% | 2026-01-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-29 | JOHN M EVANSOfficer, Director | 25K | $735K | 0.025% | 2026-01-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-22 | CHRISTINE BELLONOfficer | 1K | $47K | 0.001% | 2026-01-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-15 | CHRISTINE BELLONOfficer | 19K | $645K | 0.018% | 2026-01-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-02 | JOHN M EVANSOfficer, Director | 25K | $616K | 0.025% | 2025-10-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-01 | JOHN M EVANSOfficer, Director | 25K | $613K | 0.025% | 2025-10-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON22 holders report 5% or more of BEAM in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 12.6% of the class (12,750,369 shares), filed 2026-02-05 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 7 | ARK Investment Management LLCinvestment adviser | 10.2M | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 7 | Catherine D. Woodparent holding company, individual | 10.2M | 9.9% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Farallon Capital Management, L.L.C.investment adviser, other entity | 10.3M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Dapice Joshua J.parent holding company, individual | 10.3M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Dreyfuss, Philip D.parent holding company, individual | 10.3M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Dunn Hannah E.parent holding company, individual | 10.3M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Gehani, Varun N.parent holding company, individual | 10.3M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Giauque, Nicolasparent holding company, individual | 10.3M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Husen, Avner A.parent holding company, individual | 10.3M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Kim, David T.parent holding company, individual | 10.3M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Linn, Michael G.parent holding company, individual | 10.3M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Luo Patrick (Cheng)parent holding company, individual | 10.3M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Roberts, Jr., Thomas G.parent holding company, individual | 10.3M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Saito Edric C.parent holding company, individual | 10.3M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Short Daniel S.parent holding company, individual | 10.3M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Spokes, Andrew J. M.parent holding company, individual | 10.3M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Warren, John R.parent holding company, individual | 10.3M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Wehrly, Mark C.parent holding company, individual | 10.3M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Farallon Capital Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Farallon Capital Institutional Partners II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Farallon Capital Institutional Partners III, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Four Crossings Institutional Partners V, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Farallon Capital Offshore Investors II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Farallon Capital (AM) Investors, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Farallon Capital F5 Master I, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Farallon Healthcare Partners Master, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Farallon Partners, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Farallon Institutional (GP) V, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Farallon F5 (GP), L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Farallon Healthcare Partners (GP), L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Farallon Capital Institutional Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-04-29 | 13G | Vanguard Capital Managementinvestment adviser | 5.1M | 5.0% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 3 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-09 | 13G | STATE STREET CORPORATIONparent holding company | 5.2M | 5.2% | 2025-12-31 |
| 2026-02-05 | 13G/Ano. 5 | Fried, Richard Bindividual | 0 | 0.0% | 2025-12-31 |
| 2026-02-05 | 13G/Ano. 5 | Seybold, Williamindividual | 0 | 0.0% | 2025-12-31 |
| 2026-02-05 | 13G/Ano. 5 | Patel, Rajiv A.individual | 0 | 0.0% | 2025-12-31 |
| 2026-02-05 | 13G/Ano. 11 | FMR LLCparent holding company | 12.8M | 12.6% | 2025-12-31 |
| 2026-02-05 | 13G/Ano. 11 | Abigail P. Johnsonindividual | 12.8M | 12.6% | 2025-12-31 |
13F holders
Tracked managers holding BEAM at their latest 13F. JSON7 of the 30 tracked managers held BEAM at their latest 13F, $425.8M in total at quarter-end prices. ARK Investment Management is the largest at $351.3M (2.3% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| ARK Investment Management | 2026-06-30 | 10.2M | $351.3M | 2.28% | -1.9M |
| Two Sigma Investments | 2026-06-30 | 1.4M | $47.6M | 0.03% | +177K |
| Renaissance Technologies | 2026-06-30 | 445K | $15.3M | 0.02% | -69K |
| Duquesne Family Office | 2026-06-30 | 154K | $5.3M | 0.10% | new |
| D. E. Shaw & Co. | 2026-06-30 | 131K | $4.5M | 0.00% | new |
| Millennium Management | 2026-06-30 | 34K | $1.2M | 0.00% | +12K |
| AQR Capital Management | 2026-06-30 | 20K | $676K | 0.00% | +4K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Beam Therapeutics reported revenue of $490K, down 94.2% from the same quarter a year earlier, and net loss of $122.7M (-1.18 diluted EPS). In FY 2025 it generated -$345.1M of operating cash flow. As of 2026-06-30, cash was $219.8M against $100.3M of debt.
- Cash
- $219.8M
- Debt
- $100.3M
- Equity
- $1.07B
- Total assets
- $1.39B
- Shares outstanding
- 103,287,665
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $490K | -$122.7M | -25036.3% | -1.18 |
| Q1 FY 2026 | 2026-03-31 | $31.7M | -$94.3M | -297.2% | -0.91 |
| Q4 FY 2025derived | 2025-12-31 | $114.1M | $243.2M | 213.1% | n/a |
| Q3 FY 2025 | 2025-09-30 | $9.7M | -$112.7M | -1162.4% | -1.10 |
| Q2 FY 2025 | 2025-06-30 | $8.5M | -$102.1M | -1206.4% | -1.00 |
| Q1 FY 2025 | 2025-03-31 | $7.5M | -$108.3M | -1450.2% | -1.23 |
| Q4 FY 2024derived | 2024-12-31 | $30.1M | -$90.4M | -300.5% | n/a |
| Q3 FY 2024 | 2024-09-30 | $14.3M | -$96.7M | -677.5% | -1.17 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $139.7M | -$80.0M | -$345.1M | $14.9M | n/a | n/a |
| FY 2024 | 2024-12-31 | $63.5M | -$376.7M | -$347.2M | $8.9M | n/a | n/a |
| FY 2023 | 2023-12-31 | $377.7M | -$132.5M | -$149.2M | $33.7M | n/a | n/a |
| FY 2022 | 2022-12-31 | $60.9M | -$289.1M | $22.5M | $49.0M | n/a | n/a |
| FY 2021 | 2021-12-31 | $51.8M | -$370.6M | -$66.3M | $46.8M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-28 from the cover page.
What this page is
Beam Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Beam Therapeutics (BEAM), SEC CIK 1745999, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-04.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-07-27.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-04.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-01.JSON and CSV
- Company record
- EDGAR filing index for CIK 1745999Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
- MRNAModerna
- TWSTTwist Bioscience
- ADPTAdaptive Biotechnologies
- NVAXNovavax
- RXRXRecursion Pharmaceuticals
- DNAGinkgo Bioworks Holdings
- PCVXVaxcyte
- NBIXNeurocrine Biosciences
- VIRVir Biotechnology
- EXELExelixis
- RVMDRevolution Medicines
- GILDGilead Sciences
- HALOHalozyme Therapeutics
- KYMRKymera Therapeutics
- AMGNAmgen
- KRYSKrystal Biotech
- RGENRepligen
- VCELVericel
- BIIBBiogen
- CRSPCRISPR Therapeutics
- DNLIDenali Therapeutics
- KODKodiak Sciences
- BDTXBlack Diamond Therapeutics
- TECHBio-Techne
Datasets
Frequently Asked Questions
How much of BEAM is sold short?
27,548,815 shares were held short at the 2026-09-30 settlement, 15.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is BEAM's daily short volume?
On 2026-10-09, 348,480 of the 706,474 BEAM shares reported to FINRA were sold short, 49.3% of the day's reported volume. Short volume is a flow for one day, not a position.
Does BEAM have fails to deliver?
The SEC's latest file shows 2,930 BEAM shares failed to deliver at settlement 2026-09-04. Fails are reported per settlement date and published twice a month with a lag.
Are BEAM insiders buying or selling?
Insiders at BEAM reported 2 open-market sells worth $434K in the last 90 days and no open-market buys. Latest filing: Cavanagh Bethany J (SVP, Finance and Treasurer) on 2026-10-01.
Have BEAM insiders filed to sell?
17 Form 144 notices on file for BEAM worth $13.4M at the prices reported; 1 in the last 90 days worth $429K. Latest: AMY SIMON filed on 2026-07-27 to sell 16,677 shares ($429K) from 2026-07-27.
Who owns 5% or more of BEAM?
22 holders report 5% or more of BEAM in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 12.6% of the class (12,750,369 shares), filed 2026-02-05 for an event on 2025-12-31.
What did BEAM report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Beam Therapeutics reported revenue of $490K, down 94.2% from the same quarter a year earlier, and net loss of $122.7M (-1.18 diluted EPS). In FY 2025 it generated -$345.1M of operating cash flow. As of 2026-06-30, cash was $219.8M against $100.3M of debt.
Which tracked 13F managers own BEAM?
7 of the 30 tracked 13F managers held BEAM shares at their latest filing, $425.8M in all. The largest: Cathie Wood's ARK Investment Management (10.2M shares, $351.3M), Two Sigma Investments (1.4M shares, $47.6M), Renaissance Technologies (445K shares, $15.3M), Stanley Druckenmiller's Duquesne Family Office (154K shares, $5.3M), D. E. Shaw & Co. (131K shares, $4.5M), Izzy Englander's Millennium Management (34K shares, $1.2M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.